|
May 15
|
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
|
|
May 8
|
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 8
|
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
|
|
May 1
|
Olema Oncology to Participate in Upcoming Investor Conferences in May
|
|
Apr 8
|
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
|
|
Apr 5
|
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
|
|
Mar 11
|
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 6
|
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
|
|
Mar 4
|
Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
|
|
Jan 8
|
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
|
|
Dec 5
|
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
|
|
Dec 4
|
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 1
|
Top Stocks for December 2023
|
|
Nov 28
|
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
|
|
Nov 27
|
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
|
|
Nov 27
|
This Small Cap Is My Stock Pick, as the Market Shakes Its Hangover
|
|
Oct 26
|
12 Best Performing NASDAQ Stocks in 2023
|
|
Oct 22
|
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
|